343 related articles for article (PubMed ID: 20073555)
1. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
Bur M; Huwer H; Muys L; Lehr CM
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
[TBL] [Abstract][Full Text] [Related]
2. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
Hein S; Bur M; Schaefer UF; Lehr CM
Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
[TBL] [Abstract][Full Text] [Related]
3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
4. Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate.
Raula J; Rahikkala A; Halkola T; Pessi J; Peltonen L; Hirvonen J; Järvinen K; Laaksonen T; Kauppinen EI
Int J Pharm; 2013 Jan; 441(1-2):248-54. PubMed ID: 23200957
[TBL] [Abstract][Full Text] [Related]
5. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery.
Tewes F; Paluch KJ; Tajber L; Gulati K; Kalantri D; Ehrhardt C; Healy AM
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):604-13. PubMed ID: 23563102
[TBL] [Abstract][Full Text] [Related]
6. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
7. The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.
Begat P; Morton DA; Staniforth JN; Price R
Pharm Res; 2004 Oct; 21(10):1826-33. PubMed ID: 15553229
[TBL] [Abstract][Full Text] [Related]
8. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
[TBL] [Abstract][Full Text] [Related]
9. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
[TBL] [Abstract][Full Text] [Related]
10. A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations.
Bur M; Rothen-Rutishauser B; Huwer H; Lehr CM
Eur J Pharm Biopharm; 2009 Jun; 72(2):350-7. PubMed ID: 18771729
[TBL] [Abstract][Full Text] [Related]
11. Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?
Ong HX; Traini D; Loo CY; Sarkissian L; Lauretani G; Scalia S; Young PM
Eur J Pharm Biopharm; 2015 Jun; 93():320-7. PubMed ID: 25930239
[TBL] [Abstract][Full Text] [Related]
12. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
[TBL] [Abstract][Full Text] [Related]
13. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
14. In vitro dry powder inhaler formulation performance considerations.
Ziffels S; Bemelmans NL; Durham PG; Hickey AJ
J Control Release; 2015 Feb; 199():45-52. PubMed ID: 25497311
[TBL] [Abstract][Full Text] [Related]
15. Effect of milling and sieving on functionality of dry powder inhalation products.
Steckel H; Markefka P; teWierik H; Kammelar R
Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
[TBL] [Abstract][Full Text] [Related]
16. Permeation of Therapeutic Drugs in Different Formulations across the Airway Epithelium In Vitro.
Meindl C; Stranzinger S; Dzidic N; Salar-Behzadi S; Mohr S; Zimmer A; Fröhlich E
PLoS One; 2015; 10(8):e0135690. PubMed ID: 26274590
[TBL] [Abstract][Full Text] [Related]
17. Novel Budesonide Particles for Dry Powder Inhalation Prepared Using a Microfluidic Reactor Coupled With Ultrasonic Spray Freeze Drying.
Saboti D; Maver U; Chan HK; Planinšek O
J Pharm Sci; 2017 Jul; 106(7):1881-1888. PubMed ID: 28285981
[TBL] [Abstract][Full Text] [Related]
18. Functional similarity of modified cascade impactor to deposit drug particles on cells.
Kumar V; Bariwal J; Narang AS; Tso J; Cheong J; Mahato RI
Int J Pharm; 2020 Jun; 583():119404. PubMed ID: 32387312
[TBL] [Abstract][Full Text] [Related]
19. Dry powder inhaler device influence on carrier particle performance.
Donovan MJ; Kim SH; Raman V; Smyth HD
J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
[TBL] [Abstract][Full Text] [Related]
20. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
